Post-Marketing Clinical Study of High-Pressure Cutting Balloon
NCT07835178
Summary
This study is designed as a prospective, multicenter, 1:1 randomized controlled trial. It plans to enroll 280 patients with moderate-to-severe calcified coronary lesions who are candidates for IVUS-guided DES implantation. Subjects will be randomized in a 1:1 ratio to the experimental group (n=140) or the control group (n=140). The primary endpoint is the MSA measured by IVUS immediately after the procedure, with the purpose of verifying the safety and efficacy of the high-pressure cutting balloon in optimizing stent implantation outcomes.
Eligibility
Inclusion Criteria: * Age ≥18 years; * Patients with coronary artery disease who indicate IVUS-guided drug-eluting stent implantation; * Moderate-to-severe calcified lesions on coronary angiography; * Target lesion is a de novo lesion in a native vessel that has not received any prior interventional treatment; * Target vessel diameter of 2.5-4.0 mm, with guidewire crossing of the target lesion; * In patients with multiple lesions, only one lesion will be selected as the target lesion in this study. If target and non-target lesions are treated during the same procedure, the target and non-target lesions must be located in different vessel branches; furthermore, the non-target lesion must be treated first, and the target lesion may be treated only after successful revascularization of the non-target lesion without severe angiographic complications; * Provision of written informed consent. Exclusion Criteria: * Life expectancy \<1 year; * Cardiogenic shock or hemodynamic instability; * Left main coronary artery disease; * Chronic total occlusion; * Bifurcation lesions planned for a "two-stent strategy"; * Active bleeding; * Known history of allergy to contrast media or metals; * Patients with a bleeding tendency, contraindications to antiplatelet or anticoagulant therapy, or inability to receive anticoagulation therapy; * New-onset stroke/transient ischemic attack within 6 months; * Pregnant or lactating women; * Left ventricular ejection fraction \<25%, or NYHA functional class IV, or Killip class ≥2; * Non-target vessel revascularization within 30 days before randomization with complications.
Conditions3
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07835178